Quick Answer
REGENEREX PHARMA, INC. reported Research And Development Expense of $662.5 thousand for the year ending 2025.
- REGENEREX PHARMA, INC. showed a decrease of -72.4% in Research And Development Expense from 2024 to 2025.
- This data is from REGENEREX PHARMA, INC.'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $300.00 | Q3 2023: $2.40 million | Q4 2024: $17.4 thousand | Q3 2025: $136.4 thousand.
- Historical annual values: Fiscal year 2025: $662.5 thousand | Fiscal year 2024: $2.40 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: